Radiation Treatment of Head and Neck Cancer

Surgical Oncology Clinics of North America

Volumn 24, Issue 3, 2015, Pages 423-436

  Yom, Sue S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Head and neck; Radiation; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED RADIOTHERAPY; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OROPHARYNX CANCER; ORTHOVOLTAGE UNIT; PAPILLOMAVIRUS INFECTION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TONGUE CANCER; HEAD AND NECK NEOPLASMS; RADIATION DOSE FRACTIONATION;

DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84929320613     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2015.03.015     Document Type: Review

References (67)

1. Thwaites D.I., Tuohy J.B. Back to the future: the history and development of the clinical linear accelerator. Phys Med Biol 2006, 51:R343-R362.
2. Intensity Modulated Radiation Therapy Collaborative Working Group Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001, 51:880-914.
3. Bucci M.K., Bevan A., Roach M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005, 55:117-134.
4. Mell L.K., Mehrotra A.K., Mundt A.J. Intensity-modulated radiation therapy use in the US, 2004. Cancer 2005, 104:1296-1303.
5. Wyckoff H.O., Allisy A., Liden K. The new special names of SI units in the field of ionizing radiation. Acta Radiol Ther Phys Biol 1975, 14:590-591.
6. Kubicek G.J., Machtay M. New advances in high-technology radiotherapy for head and neck cancer. Hematol Oncol Clin North Am 2008, 22:1165-1180. viii.
7. Rusthoven K.E., Raben D., Ballonoff A., et al. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 2008, 118:635-639.
8. Lohia S., Rajapurkar M., Nguyen S.A., et al. Acomparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2014, 140:331-337.
9. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT): contents. JICRU 2010, 10:NP.
10. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. JClin Oncol 2007, 25:4873-4879.
11. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991.
12. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136.
13. Studer G., Linsenmeier C., Riesterer O., et al. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol 2013, 8:259.
14. Ben-David M.A., Diamante M., Radawski J.D., et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007, 68:396-402.
15. Studer G., Studer S.P., Zwahlen R.A., et al. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2006, 182:283-288.
16. Eisbruch A., Schwartz M., Rasch C., et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys 2004, 60:1425-1439.
17. Roe J.W., Carding P.N., Dwivedi R.C., et al. Swallowing outcomes following intensity modulated radiation therapy (IMRT) for head & neck cancer-a systematic review. Oral Oncol 2010, 46:727-733.
18. Rosenthal D.I., Chambers M.S., Fuller C.D., et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 72:747-755.
19. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. NEngl J Med 1991, 324:1685-1690.
20. Forastiere A.A., Zhang Q., Weber R.S., et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. JClin Oncol 2013, 31:845-852.
21. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. JNatl Cancer Inst 1996, 88:890-899.
22. Chua M., Sze O.W., Wee J., et al. Plasma EBV DNA as a predictive biomarker in patients with endemic nasopharyngeal carcinoma treated with induction chemotherapy and concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys 2014, 90:S120-S121.
23. Cohen E.E., Karrison T.G., Kocherginsky M., et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. JClin Oncol 2014, 32:2735-2743.
24. Haddad R., O'Neill A., Rabinowits G., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013, 14:257-264.
25. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. NEngl J Med 2007, 357:1705-1715.
26. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. JClin Oncol 2003, 21:92-98.
27. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. JClin Oncol 2004, 22:69-76.
28. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. JClin Oncol 1998, 16:1310-1317.
29. Wee J., Tan E.H., Tai B.C., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. JClin Oncol 2005, 23:6730-6738.
30. Pignon J.P., le Maitre A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
31. Trotti A., Pajak T.F., Gwede C.K., et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007, 8:613-624.
32. Garden A.S., Kies M.S., Morrison W.H., et al. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol 2013, 8:21.
33. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. NEngl J Med 2010, 363:24-35.
34. O'Sullivan B., Huang S.H., Siu L.L., et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. JClin Oncol 2013, 31:543-550.
35. Kimple R.J., Harari P.M. Is radiation dose reduction the right answer for HPV-positive head and neck cancer?. Oral Oncol 2014, 50:560-564.
36. Pfister D.G., Ang K.K., Brizel D.M., et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. JNatl Compr Canc Netw 2013, 11:917-923.
37. Ridge J.A. Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol 1993, 20:419-429.
38. Goodwin W.J. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?. Laryngoscope 2000, 110:1-18.
39. Manikantan K., Khode S., Dwivedi R.C., et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev 2009, 35:744-753.
40. Paniello R.C., Virgo K.S., Johnson M.H., et al. Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2professional societies. Arch Otolaryngol Head Neck Surg 1999, 125:309-313.
41. Ryan W.R., Fee W.E., Le Q.T., et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005, 115:645-650.
42. Mancuso A.A. The "third-best" strategy for treating head and neck cancer. AJNR Am J Neuroradiol 1999, 20:1191-1192.
43. Fakhry C., Zhang Q., Nguyen-Tan P.F., et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. JClin Oncol 2014, 32:3365-3373.
44. Yao M., Hoffman H.T., Chang K., et al. Is planned neck dissection necessary for head and neck cancer after intensity-modulated radiotherapy?. Int J Radiat Oncol Biol Phys 2007, 68:707-713.
45. McHam S.A., Adelstein D.J., Rybicki L.A., et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?. Head Neck 2003, 25:791-798.
46. Soltys S.G., Choi C.Y., Fee W.E., et al. Aplanned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:994-999.
47. Nayak J.V., Walvekar R.R., Andrade R.S., et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007, 117:2129-2134.
48. Igidbashian L., Fortin B., Guertin L., et al. Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010, 77:414-420.
49. Brizel D.M., Prosnitz R.G., Hunter S., et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 58:1418-1423.
50. Hofer S.O., Shrayer D., Reichner J.S., et al. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998, 133:383-389.
51. Sieweke M.H., Bissell M.J. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog 1994, 5:297-311.
52. Peters L.J., Goepfert H., Ang K.K., et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993, 26:3-11.
53. Ang K.K., Trotti A., Brown B.W., et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 51:571-578.
54. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. NEngl J Med 2004, 350:1945-1952.
55. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. NEngl J Med 2004, 350:1937-1944.
56. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843-850.
57. Rosenthal D.I., Harris J., Forastiere A.A., et al. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. JClin Oncol 2009, 27:4727-4732.
58. Tupchong L., Scott C.B., Blitzer P.H., et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 1991, 20:21-28.
59. Puc M.M., Chrzanowski Jr F.A., Tran H.S., et al. Preoperative chemotherapy-sensitized radiation therapy for cervical metastases in head and neck cancer. Arch Otolaryngol Head Neck Surg 2000, 126:337-342.
60. Wanebo H.J., Glicksman A.S., Landman C., et al. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. Am J Surg 1995, 170:512-516.
61. Klug C., Berzaczy D., Voracek M., et al. Preoperative chemoradiotherapy in the management of oral cancer: a review. JCraniomaxillofac Surg 2008, 36:75-88.
62. Onizawa K., Yoshida H., Ohara K., et al. Predictive factors for the histologic response to preoperative radiotherapy in advanced oral cancer. JOral Maxillofac Surg 2006, 64:81-86.
63. Licitra L., Grandi C., Guzzo M., et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. JClin Oncol 2003, 21:327-333.
64. Grau J.J., Domingo J., Blanch J.L., et al. Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology 2002, 63:338-345.
65. Laramore G.E. Role of particle radiotherapy in the management of head and neck cancer. Curr Opin Oncol 2009, 21:224-231.
66. Ahn P.H., Lukens J.N., Teo B.K., et al. The use of proton therapy in the treatment of head and neck cancers. Cancer J 2014, 20:421-426.
67. Kamada T., Tsujii H., Blakely E.A., et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 2015, 16:e93-e100.